Compare UCAR & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCAR | GOVX |
|---|---|---|
| Founded | 2013 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 7.8M |
| IPO Year | 2023 | N/A |
| Metric | UCAR | GOVX |
|---|---|---|
| Price | $1.45 | $0.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $7.00 |
| AVG Volume (30 Days) | 14.4K | ★ 3.7M |
| Earning Date | 10-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,816,075.00 | $3,353,560.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 57.22 | 8.52 |
| 52 Week Low | $1.43 | $0.12 |
| 52 Week High | $9.43 | $2.75 |
| Indicator | UCAR | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 24.03 | 35.02 |
| Support Level | $1.57 | $0.16 |
| Resistance Level | $1.80 | $0.22 |
| Average True Range (ATR) | 0.16 | 0.04 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 8.51 | 34.27 |
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.